Impact of dried brewers’ grains supplementation on performance, metabolism and meat quality of broiler chickens

The objective was to evaluate increasing levels of dried brewers’ grains (DBG) in feed for broiler chickens from 1 to 21 days old and their effect on performance, blood parameters, intestinal morphometry, carcass characteristics and meat quality. The design was completely randomized with six treatments, which consisted of various levels of DBG inclusion, namely 0 (no inclusion), 20, 40, 60, 80, and 100 g/kg with seven replications and 17 animals per experimental unit, totalling 714 male broilers. Performance parameters, blood biochemical profile, morphology of the intestinal epithelium (duodenum), and carcass yield and composition were evaluated. Feed intake was not changed by DBG inclusion levels. Nor were weight gain and feed conversion ratio. Serum cholesterol levels were not influenced, and there were no effects on triglyceride, uric acid and creatinine levels. Enzyme aspartate aminotransferase showed a quadratic effect, as did alanine aminotransferase, with higher values at 79.5 and 63.9 g/kg DBG inclusion, respectively. No changes in carcass yield and relative organ weight were observed. The composition of the carcass in ether extract showed a quadratic effect, as fat deposition rate, with lowest values at 62.8 and 62.4 g/kg of DBG inclusion levels, respectively. Crude protein levels in carcass reduced linearly, as did fat deposition rate. The parameters of intestinal morphology and meat quality were not changed. Dried brewers’ grains can be included in broiler diet from 1 to 21 days at levels up to 100 g/kg without influencing the metabolic parameters and broiler performance. Keywords: alternative feed, blood, by-product, intestinal villi, performanc

A lattice study of the exclusive B→K∗γB \to K^* \gamma decay amplitude, using the Clover action at β=6.0\beta=6.0

We present the results of a numerical calculation of the $B\to K^* \gamma$ form factors. The results have been obtained by studying the relevant correlation functions at $\beta=6.0$, on an $18^3 \times 64$ lattice, using the ${\rm O(a)}$-improved fermion action, in the quenched approximation. From the study of the matrix element $$ we have obtained the form factor $T_1(0)$ which controls the exclusive decay rate. The results are compared with the recent results from CLEO. We also discuss the compatibility between the scaling laws predicted by the Heavy Quark Effective Theory (HQET) and pole dominance, by studying the mass- and $q^2$-dependence of the form factors. From our analysis, it appears that the form factors follow a mass behaviour compatible with the predictions of the HQET and that the $q^2$-dependence of $T_2$ is weaker than would be predicted by pole dominance.Comment: 17 pages, LaTeX + epsf.sty. Uuencoded, compressed, tar archive including the text and one postscript figur

The ATLAS trigger system for LHC Run 3 and trigger performance in 2022

The ATLAS trigger system is a crucial component of the ATLAS experiment at the LHC. It is responsible for selecting events in line with the ATLAS physics programme. This paper presents an overview of the changes to the trigger and data acquisition system during the second long shutdown of the LHC, and shows the performance of the trigger system and its components in the proton-proton collisions during the 2022 commissioning period as well as its expected performance in proton-proton and heavy-ion collisions for the remainder of the third LHC data-taking period (2022–2025)

Combination of searches for heavy spin-1 resonances using 139 fb−1 of proton-proton collision data at √s = 13 TeV with the ATLAS detector

A combination of searches for new heavy spin-1 resonances decaying into diferent pairings of W, Z, or Higgs bosons, as well as directly into leptons or quarks, is presented. The data sample used corresponds to 139 fb−1 of proton-proton collisions at √s = 13 TeV collected during 2015–2018 with the ATLAS detector at the CERN Large Hadron Collider. Analyses selecting quark pairs (qq, bb, tt¯, and tb) or third-generation leptons (τν and τ τ ) are included in this kind of combination for the frst time. A simplifed model predicting a spin-1 heavy vector-boson triplet is used. Cross-section limits are set at the 95% confdence level and are compared with predictions for the benchmark model. These limits are also expressed in terms of constraints on couplings of the heavy vector-boson triplet to quarks, leptons, and the Higgs boson. The complementarity of the various analyses increases the sensitivity to new physics, and the resulting constraints are stronger than those from any individual analysis considered. The data exclude a heavy vector-boson triplet with mass below 5.8 TeV in a weakly coupled scenario, below 4.4 TeV in a strongly coupled scenario, and up to 1.5 TeV in the case of production via vector-boson fusion

Measurement of vector boson production cross sections and their ratios using pp collisions at √s = 13.6 TeV with the ATLAS detector

Abstract available from publisher's website

Partial replacement of DL-Methionine and methionine hydroxy analogue with betaine in diets for broiler chickens

The study evaluated the effects on the growth performance and carcass characteristics of broiler chickens of DL-Methionine (DL-Met) and methionine hydroxy analogue (MHA) supplementation and their partial replacement with betaine (Bet). Two experiments were performed from day 1 to 21 and from day 22 to 42. Broiler chickens were assigned to six treatments, in a completely randomized design and a 2 × 2 + 2 factorial arrangement, consisting of two Met sources (DL-Met and MHA), with or without Bet, and two negative controls. The six treatments consisted of i) NC-DLM: negative control for DL-Met with 7% reduction in DL-Met; ii) NC-MHA: negative control for MHA with 7% reduction of MHA, iii) DLM100: without Bet, supplemented exclusively with DL-Met reaching 100% of requirements, iv) MHA100: without Bet supplemented exclusively with MHA reaching 100% of requirements, v) DLM93+Bet: DL-Met at 93% of recommended level plus betaine; vi) MHA93+Bet: MHA at 93% of recommended level plus betaine. Growth from day 1 to 21 was not altered by methionine source or betaine supplementation. However, the negative controls had numerically less weight gain and feed conversion ratio (FCR) . Between days and 42 there were no effects on growth. Betaine could partially replace methionine without altering the growth of broiler chickens. In addition, the partial replacement of DL-Met with betaine increased body crude protein content. However, its use increased body fat content regardless of methionine source

Treatments for colorectal liver metastases: A new focus on a familiar concept

A major challenge for the management of advanced-colorectal-cancer is the multidisciplinary approach required for the treatment of liver metastases. Reducing the burden of liver metastases with liver-directed therapy has an important impact on both survival and health-related quality of life. This paper debates the rationale and current liver-directed approaches for colorectal liver metastases based on the evidence of literature and new clinical trials. Surgery is the gold standard, when feasible, and it's the main treatment goal for patients with potentially-resectable disease as a means of prolonging progression-free survival. Better tumor response rates with modern systemic therapy mean that more unresectable patients are now down-staged for radical resection following conversion therapy but for other patients, additional procedures are needed. In multiple unilobar disease, when the projected remnant liver is <30% of the total liver, portal embolization or selective-internal-radiation-therapy (SIRT) can induce hypertrophy of the healthy liver, leading to resectability. In multiple bilobar disease, in situ destruction of non-resectable lesions by minimally invasive techniques may be associated with liver resection to achieve potential curative intent. Other palliative liver-directed approaches, such as SIRT or intra-hepatic chemotherapy (HAI), which are associated with higher response rates, may also have role in down-staging patients for resection. Until recently, such technologies have not been validated in prospective controlled trials. However in the light of new Phase 3 data for SIRT as well as for HAI combined with modern therapies or radiofrequency ablation in the first- and second-line setting, the clinical value of these treatments needs to be re-appraised